Market closedNon-fractional

Ventyx Biosciences/VTYX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ticker

VTYX

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

San Diego, United States

Employees

74

VTYX Metrics

BasicAdvanced
$154M
Market cap
-
P/E ratio
-$3.23
EPS
0.47
Beta
-
Dividend rate
$154M
0.47
22.001
20.819
3.436
3.744
-35.91%
-56.76%
0.5
0.5
-0.707
40.65%
-52.64%

What the Analysts think about VTYX

Analyst Ratings

Majority rating from 10 analysts.
Buy

VTYX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$39M
-17.56%
Profit margin
0.00%
NaN%

VTYX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.65%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.91
-$0.92
-$0.79
-$0.62
-
Expected
-$0.71
-$0.90
-$0.90
-$0.69
-$0.58
Surprise
27.97%
2.73%
-12.55%
-9.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ventyx Biosciences stock?

Ventyx Biosciences (VTYX) has a market cap of $154M as of July 06, 2024.

What is the P/E ratio for Ventyx Biosciences stock?

The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of July 06, 2024.

Does Ventyx Biosciences stock pay dividends?

No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Ventyx Biosciences dividend payment date?

Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.

What is the beta indicator for Ventyx Biosciences?

Ventyx Biosciences (VTYX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Ventyx Biosciences stock

Buy or sell Ventyx Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing